Evidence map›Paper›PMID 36031906›Full record

ArticleJournal of neuromuscular diseases2022

Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study.

Lauren Elman, Bora Youn, Crystal M Proud, Margaret R Frey, Senda Ajroud-Driss, M Eileen McCormick, David Michelson, Michael S Cartwright, Terry Heiman-Patterson, Joseph M Choi and 4 more

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuromuscular diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Lauren ElmanUniversity of Pennsylvania, Philadelphia, PA, USA.
Bora YounBiogen, Cambridge, MA, USA.
Crystal M ProudChildren's Hospital of the King's Daughters, Norfolk, VA, USA.
Margaret R FreyMemorial Healthcare Institute for Neuroscience, Owosso, MI, USA.
Senda Ajroud-DrissNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
M Eileen McCormickOakland University William Beaumont School of Medicine, Royal Oak, MI, USA.
David MichelsonLoma Linda University Health, Loma Linda, CA, USA.
Michael S CartwrightWake Forest School of Medicine, Winston-Salem, NC, USA.
Terry Heiman-PattersonLewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Joseph M ChoiGeorgetown University Hospital, Washington, DC, USA.
Aastha ChandakCertara, New York, NY, USA.
Artak KhachatryanCertara, London, UK.
Marta MartinezCertara, London, UK.
Angela D ParadisBiogen, Cambridge, MA, USA.
Biogen (United States) · USCertara (United States) · USChildren's Hospital of The King's Daughters · USGeorgetown University · USLoma Linda University · USNorthwestern University · USOakland University · USTemple University · USUniversity of Pennsylvania · USWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limited evidence exists on real-world adherence to nusinersen for the treatment of spinal muscular atrophy (SMA). Data are presented from a multi-site retrospective chart review of 86 adults with SMA initiating nusinersen at nine US centers between January 2017 and February 2019. Seventy-nine (92%) adults remained on nusinersen during the study; 454 (92%) of 493 total nusinersen doses were received on time. Fifty-eight (67%) adults received all nusinersen doses on time. The majority of patients with at least one nonadherent dose resumed nusinersen on time. Most patients followed the dosing schedule across the loading and maintenance dose periods.

Indexed as

Muscular Atrophy, SpinalAdultHumansOligonucleotidesRetrospective StudiesnusinersenOligonucleotidesadultsantisense oligonucleotidesMedication adherenceneuromuscular diseasesretrospective studiesspinal muscular atrophy

Identifiers

PMID36031906
PMCPMC9535601
OpenAlexW4292840124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.